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GABA release from interneurons in VTA, projections
from the nucleus accumbens (NAc), and rostrome-
dial tegmental nucleus (RMTg) was selectively
activated in rat brain slices. The inhibition induced
by m-opioid agonists was pathway dependent.
Morphine induced a 46% inhibition of IPSCs evoked
from the RMTg, 18% from NAc, and IPSCs evoked
from VTA interneurons were almost insensitive
(11% inhibition). In vivo morphine treatment resulted
in tolerance to the inhibition of RMTg, but not local
interneurons or NAc, inputs. One common sign of
opioid withdrawal is an increase in adenosine-
dependent inhibition. IPSCs evoked from the NAc
were potently inhibited by activation of presynaptic
adenosine receptors, whereas IPSCs evoked from
RMTg were not changed. Blockade of adenosine
receptors selectively increased IPSCs evoked from
the NAc duringmorphine withdrawal. Thus, the acute
action of opioids, the development of tolerance, and
the expression of withdrawal are mediated by sepa-
rate GABA afferents to dopamine neurons.
INTRODUCTION
Dopamine neurons in the ventral tegmental area (VTA) and
substantia nigra pars compacta (SNc) respond by burst firing
following salient stimuli, motivation, or impulsive movement
(Bromberg-Martin et al., 2010; Schultz, 2007). The rate and
pattern of dopamine neuron firing is tightly controlled by the
balance of intrinsic activity and synaptic input. The GABA input
from areas including the substantia nigra pars reticulata (SNr),
nucleus accumbens (NAc), ventral pallidum/globus pallidus,
the rostromedial tegmental nucleus (RMTg), laterodorsal
tegmentum, pedunculopontine nuclei and diagonal band of
Broca, and bed nucleus of the stria terminalis make up at least
70% of synaptic input to dopamine neurons (Bolam and Smith,
1990; Charara et al., 1996; Kalivas et al., 1993; Omelchenko
and Sesack, 2005; Tepper et al., 1995; Tepper and Lee, 2007;
Watabe-Uchida et al., 2012). Tonic GABA input is sufficient to1346 Neuron 82, 1346–1356, June 18, 2014 ª2014 Elsevier Inc.suppress burst firing even with excitatory inputs intact (Jalabert
et al., 2011; Lobb et al., 2010). Thus, it is important to understand
the mechanisms that modulate the release of GABA onto dopa-
mine neurons.
GABA input to dopamine neurons is reduced by the activation
of m-opioid receptors (MORs), resulting in an increase in the firing
rate of dopamine neurons originally thought to be mediated by
local interneurons (Gysling andWang, 1983; Johnson and North,
1992). Recently, neurons in the RMTg were found to send a
dense opioid-sensitive GABA input to dopamine neurons (Jhou
et al., 2009; Kaufling et al., 2009), suggesting that the local inter-
neurons may not be the major site of action of opioids (Jalabert
et al., 2011). Additionally, projections from the NAc also synapse
onto dopamine neurons (Cui et al., 2014; Kalivas et al., 1993;
Watabe-Uchida et al., 2012), although that innervation is less
dense than the innervation of GABA cells in the VTA (Bocklisch
et al., 2013; Xia et al., 2011).
With repeated administration of opioids, tolerance, depen-
dence, and addiction can develop, driven through adaptive
mechanisms initiated in the mesolimbic pathway. Cellular toler-
ance to opioids, determined by the reduction in efficacy, has
been observed postsynaptically in multiple assays (Christie
et al., 1987; Connor et al., 1999; Sim et al., 1996; Williams
et al., 2013). On the other hand, opioid actions at presynaptic
terminals following repeated morphine treatment has been re-
ported to be increased or decreased in different brain areas
such as the periaqueductal gray (PAG) and arcuate nucleus
(Fyfe et al., 2010; Hack et al., 2003; Ingram et al., 1998; Pennock
and Hentges, 2011), including GABA terminals in the VTA (Lowe
and Bailey, 2014). One hallmark of the withdrawal frommorphine
is the development of a cAMP-dependent increase in the prob-
ability of GABA release in the VTA. The opioid sensitivity of
GABA inputs from interneurons, the RMTg, and the NAc has
not been examined following chronic morphine treatment.
The present study examines GABA inhibitory postsynaptic
currents (IPSCs) on dopamine neurons evoked from three
different afferent pathways: interneurons, the NAc, and the
RMTg. In order to activate GABA afferent pathways selectively,
channelrhodopsin-2 (ChR2) was expressed in each region, and
blue light (473 nm) was used to initiate transmitter release. The
inhibition of IPSCs by the opioid agonists [Met5]enkephalin,
DAMGO, and morphine was examined in each pathway in slices
taken from untreated andmorphine-treated animals (MTAs). The
results show projection-specific (1) sensitivity to opioids, (2)
Figure 1. Opioids Cause a Small Inhibition of GABA-A IPSCs Origi-
nating from the VTA/SN
Images of brain sections with Gad65/67 (green) labeled by fluorescent in situ
hybridization and ChR2 (red) immunolabeled against Venus show GABA
neurons within the VTA/SN that express ChR2.
(A) Medial sagittal slice of the midbrain containing the VTA. ChR2 expression
was restricted within the VTA. Inset shows an enlarged view of the boxed area.
Some cells showing colocalization of Gad65/67 and ChR2 are indicated with
asterisks.
(B) Lateral sagittal slice containing the substantia nigra pars compacta (SNc)
and reticulata (SNr). ChR2 expression was observed in SNc and SNr. RMTg,
rostromedial tegmental nucleus; VTA, ventral tegmental area; 3n, oculomotor
nerve; MT, medial terminal nucleus of accessory optic tract.
(C) Superimposed traces of paired GABA-A IPSCs in a dopamine neuron.
GABA-A IPSCs were inward because of the high chloride internal solution.
(D) Superimposed traces of IPSCs in a CIN.
(E) Summary graph of the inhibition of IPSCs in dopamine neurons and CINs.
DAMGO (1 mM) significantly decreased IPSC amplitude to a similar extent in
both neuronal populations. U69593 (1 mM) caused a small and significant in-
hibition of the IPSC amplitude in dopamine neurons, but not in CINs. Quinpirole
or dopamine did not change the IPSC amplitude in either cell type. Results
from individual experiments are shown as dots. In this and all other figures, the
number in the parentheses indicates the total number of animals used in the
particular experiment. Traces shown are averages of five sweeps. Error bars
indicate SEM. *p < 0.05 and **p < 0.001 by one-sample Student’s t test.
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GABA Input to the Ventral Midbraindevelopment of tolerance, and (3) adenosine-dependent
withdrawal.
RESULTS
ChR2 Expression in the VTA-Dopamine and GABA
Neurons
Injection of AAV-DJ (100 nl, AAV-CAG-ChR2-Venus) resulted
in the expression of ChR2 that was limited to small regions ofthe VTA and substantia nigra (SN) (Figures 1A and 1B). Fluo-
rescent in situ hybridization was used to detect mRNA for
GAD65 and GAD67 (Jarvie and Hentges, 2012), the enzymes
responsible for GABA synthesis. Gad65/67 expression was
found in areas known to contain GABA neurons, including the
VTA and SN. The number of neurons that expressed ChR2 was
counted from six injection sites from three animals. Of the
ChR2-positive neurons in both the VTA and SN, 21.7% ex-
pressed Gad65/Gad67 mRNA (Figures 1A and 1B; 418/1,924
neurons; n = 6 injections). Previous reports indicated that
approximately 30%–35% of VTA and 20% of SNc neurons are
GABAergic (Dobi et al., 2010; Nair-Roberts et al., 2008; Van
Bockstaele and Pickel, 1995). Thus, ChR2 was expressed in
both GABA and non-GABA neurons in the VTA and SN. Given
the heterogeneity of neurons in the SNc and VTA, ChR2 expres-
sion in non-GABA neurons is most likely in both dopamine and
glutamate neurons (Yamaguchi et al., 2011). Differences be-
tween the cellular properties of glutamate and dopamine
neurons in the VTA have not been identified, with the possible
exception of the projections to the medial prefrontal cortex
that are insensitive to dopamine (Lammel et al., 2008). Neurons
in the present study were considered to be dopamine neurons
based on a combination of intrinsic properties and the sensitivity
to dopamine as described previously (Chieng et al., 2011; Ford
et al., 2006).
GABA-A IPSCs from Interneurons in the VTA Were
Sensitive to Opioids
Whole-cell voltage clamp recordings were made from dopamine
neurons, and focal (20–100 mm diameter) laser stimulation (3 ms
paired flashes 50 ms apart) was applied every 30 s. All experi-
ments were carried out in the presence of DNQX (10 mM) and
MK801 (pretreated with 10 mM for 30min) to rule out possible
interference resulting from the polysynaptic release of GABA.
Activation of ChR2-expressing GABA interneurons in the VTA
resulted in inward IPSCs induced by the activation of GABA-A
receptors (ECl = 14 mV). In some cases, a small inward current
was induced by the direct activation of ChR2 in the recorded
neuron followed by a GABA-A IPSC. In such experiments, the
direct ChR2 current was subtracted from GABA-A IPSCs post
hoc following the application of GABA-A receptor antagonist
(picrotoxin, 100 mM, or SR 95531, 3 mM). The ChR2-evoked
GABA-A IPSCs were blocked with the sodium channel blocker
tetrodotoxin (TTX) (300 nM); thus, GABA-A IPSCs were depen-
dent on presynaptic action potentials. Varying the duration of
light stimulation (2–5 ms) did not affect the sensitivity to TTX.
Application of a saturating concentration of the MOR-selective
agonist DAMGO (1 mM) significantly decreased the amplitude
of IPSCs (66.0% ± 5.3% of control; n = 10, four animals; t9 =
6.47; p < 0.001, Student’s t test) (Figures 1C and 1E). To examine
whether the opioid inhibition of GABA-A IPSCs was mediated by
a presynaptic mechanism, the paired-pulse ratio (PPR = IPSC2/
IPSC1) was measured. The PPR increased from 0.56 ± 0.02 in
control to 0.64 ± 0.03 in the presence of DAMGO (n = 10; t9 =
2.71; p < 0.05), suggesting that the inhibition was the result of
a presynaptic mechanism. The k-opioid receptor (KOR) agonist
U69653 (1 mM) caused a very small inhibition of the GABA-A
IPSC (92.7% ± 3.1% of control; n = 23, ten animals; t22 = 2.36;Neuron 82, 1346–1356, June 18, 2014 ª2014 Elsevier Inc. 1347
Figure 2. GABA Projections from the NAc to Dopamine Neurons Are
Inhibited by MORs
ChR2 was expressed in the NAc, and GABA-A IPSCs were recorded from
dopamine neurons in the VTA. ChR2 was activated by paired LED flashes
(0.5 ms; 50 ms interval; 473 nm).
(A) Coronal image of a brain section expressing ChR2 in the NAc (green).
(B) Representative traces showing the ME (1 mM) and dopamine (3 mM)
induced inhibition of IPSCs in dopamine neurons. ME was used to test MOR
sensitivity so that the sensitivity to subsequent application of U69593 could be
observed.
(C) Summary graph of the inhibition of IPSCs in dopamine neurons and CINs.
DAMGO (1 mM) and dopamine (3 mM) significantly inhibited IPSCs. U69593
(1 mM) had no effect.
(D) Coronal image of a NAc brain section showing retrograde tracer Cholera
Toxin B (CTX)-positive neurons (i: green) and enkephalin (ENK) immuno-
positive neurons (ii: red). Insets (ii) show ENK immunoreactivity of colabeled
neurons (arrowhead). Scale bar, 50 mm and 10 mm in insets. AC, anterior
commissure; NAc, nucleus accumbens. Traces shown are averages of five
sweeps. Error bars indicate SEM. **p < 0.001 by one-sample Student’s t test.
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GABA Input to the Ventral Midbrainp = 0.03) (Figure 1E) with no change in the PPR (n = 23; t22 = 1.59;
p = 0.127).
Recently, dopamine neurons have been found to release
GABA onto medium spiny neurons (MSNs) in mouse, and the
D2-like receptor agonist quinpirole inhibited that release (Tritsch
et al., 2012). In the present study, dopamine (3–10 mM) or quin-
pirole (3 mM) failed to change the IPSC amplitude significantly
(101.5% ± 3.5% of control; n = 5, three animals; t4 = 0.43; p =
0.69 and 99.0% ± 1.9% of control; n = 12, three animals; t11 =
0.51; p = 0.62, respectively) (Figure 1E). There was no change
in the PPR with either agonist (n = 16; t16 = 0.93; p = 0.37).
Thus, the ChR2-induced GABA release was the result of the
activation of interneurons that were sensitive to inhibition by
MORs but not dopamine receptors.
Previous reports indicate that the GABA neurons in the VTA
project to the NAc (Brown et al., 2012; Van Bockstaele and
Pickel, 1995; van Zessen et al., 2012). ChR2 expression in the1348 Neuron 82, 1346–1356, June 18, 2014 ª2014 Elsevier Inc.VTA resulted in light-evoked GABA-A IPSCs in the cholinergic
interneurons (CINs) of the NAc (average amplitude 463 ±
132 pA, n = 34) (Figure 1D). The MOR agonist DAMGO (1 mM)
significantly inhibited the IPSCs in CINs (61.4 ± 2.0% of control,
n = 16, 10 animals, t15 = 19.12, p < 0.001) (Figure 1E) and
increased the PPR (from 0.47 ± 0.04 to 0.62 ± 0.04, n = 16,
t15 = 4.56, p < 0.0001, Student’s t test). As previously described,
DAMGO (1 mM) also induced an outward current (109.8 ±
24.68 pA, n = 11) (Britt and McGehee, 2008). The GABA IPSCs
were insensitive to the KOR agonist U69593 (1 mM; 100.5% ±
2.6% of control, n = 11, five animals, t10 = 0.19, p = 0.85) and
dopamine (3 mM, 109.2% ± 5.1% of control, n = 6, t5 = 1.78,
p = 0.14) (Figure 1E), suggesting that the IPSCs did not result
from the activation of dopamine afferents. The inhibition of
GABA-A IPSCs induced by DAMGO (1 mM) in CINs was similar
in magnitude to the inhibition measured in dopamine neurons
(61.4% ± 2.0% of control in CINs versus 66.0% ± 5.3% in dopa-
mine neurons). Small amplitude GABA-A IPSCs were also
observed in MSNs. GABA-A IPSCs in MSNs were significantly
inhibited by the D2-like receptor agonist quinpirole (3 mM;
36.7% ± 9.1% of control, n = 5, four animals, p = 0.002) but
were not sensitive to the opioid agonist [Met5]enkephalin (ME,
1 mM; 99.5% ± 3.8% of control, n = 5, p = 0.13). Thus, the
GABA-input from the VTA/SN to MSNs is most likely from dopa-
mine neurons, as previously reported (Tritsch et al., 2012).
ADirect D2-Receptor-Containing, MOR-Sensitive GABA
Input to DA Neurons from the NAc
Recent studies have demonstrated that dopamine neurons
receive GABA input from a specific subset of NAc neurons
(Bocklisch et al., 2013; Cui et al., 2014; Watabe-Uchida et al.,
2012); however, the strength of these synaptic connections
and the presynaptic receptors at those terminals remains
controversial (Bocklisch et al., 2013; Chuhma et al., 2011; Xia
et al., 2011). ChR2 was expressed in the NAc using a ubiquitous
promoter (CAG) in an AAV-9 serotype (Figure 2A). Additional
retrograde expression of ChR2 in dopamine neurons was
observed in the midbrain 5 weeks after viral injection (data not
shown). To avoid the activation of retrogradely labeled cells, ex-
periments were performed within 4 weeks after injection. Full-
field LED light stimulation (1–5 ms duration paired stimuli;
50 ms interval every 30 s) was applied to evoke GABA-A IPSCs
in dopamine neurons. Although GABA-A IPSCs were frequently
observed in GABA neurons in the VTA (data not shown), activa-
tion of ChR2 in terminals from the NAc also induced GABA-A
IPSCs in some VTA dopamine neurons, indicating that there is
a functional connection between the NAc and VTA dopamine
neurons (Figure 2B). The amplitude of GABA-A IPSCs in dopa-
mine neurons was significantly decreased by the MOR agonists
morphine (1 mM, 81.9%± 2.9%of control, n = 9, five animals, t8 =
6.28, p = 0.0002) and DAMGO (1 mM, 49.3% ± 4.2% of control,
n = 9, five animals, t8 = 12.1, p < 0.0001, Student’s t test); how-
ever, the KOR agonist U69593 (1 mM) did not alter the GABA-A
IPSC amplitude (96.4% ± 4.7% of control, n = 6, five animals,
t5 = 0.78, p = 0.47) (Figure 2C). In addition, dopamine (3 mM)
also significantly decreased GABA-A IPSC amplitude (55.7% ±
5.3% of control, n = 9, four animals, t8 = 8.29, p < 0.0001). This
inhibition was mimicked with an application of D2-like receptor
Figure 3. Opioid Receptor Inhibition of IPSCs from the RMTg, NAc,
and VTA.
ChR2 was expressed either in RMTg, NAc, or VTA neurons, and GABA-A
IPSCs were recorded from dopamine neurons.
(A) Representative traces of IPSCs from RMTg, NAc, or VTA inputs.
(B) Summary graph shows percent inhibition of the IPSC byME (1 mM) for each
input.
(C) Concentration response curves of the inhibition of IPSCs by DAMGO. The
concentration response curve from the RMTg was adapted from a previous
paper (Matsui and Williams, 2011). RMTg (black), NAc (orange), and VTA (red)
inputs were constructed by recording from dopamine neurons. Traces are the
average of five sweeps. Error bars indicated SEM. *p < 0.05 and **p < 0.001 by
one-way ANOVA with Bonferroni’s post hoc test.
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GABA Input to the Ventral Midbrainagonist quinpirole (3 mM, 39.1% ± 9.0% of control, n = 3,
three animals). These results suggest that in the rat, a direct
GABAergic input from the NAc to the VTA exists that is unlike
the traditional direct pathway in the sensitivity to both MOR-
and D2-receptor agonists and not KOR agonists.
These non-canonical GABA inputs were examined anatomi-
cally using the retrograde transport of fluorescent-cholera toxin
B (CTX) from the VTA combined with immunohistochemical
identification of neurons in the NAc. The traditional D2-expresing
indirect pathway MSNs were identified as enkephalin positive
neurons believed to also express MORs. The results show
10.8%of NAc neurons projecting directly to the VTA are enkeph-
alin immunopositive (Figure 2D; 259/2438 cells, 6 injections, 3
animals). Although unexpected, the functional and anatomical
results indicate the presence of this MOR sensitive pathway.
The RMTg Is the Major Opioid-Sensitive GABA Input to
DA Neurons
The dense GABA input from the RMTg to dopamine neurons has
been previously shown to be potently inhibited by opioids
(Matsui and Williams, 2011). To determine the relative amount
of inhibition from each GABA afferent, a subsaturating concen-
tration of ME (1 mM) was applied. The GABA-A IPSCs from theRMTg were decreased by 74.5% ± 4.7% (n = 25, 11 animals,),
whereas inputs from the NAc and local VTA interneurons were
inhibited only by 45.0% ± 5.1% (n = 8, five animals) and
17.4% ± 4.2% (n = 36, 16 animals), respectively (Figures 3A
and 3B). Thus, the input from the RMTg was more strongly in-
hibited than those from the NAc or local interneurons (F(2,66) =
43.0, p < 0.0001, one-way ANOVA Bonferroni). Since ME is not
m-receptor specific, receptor subtype and sensitivity of the
different inputs was further characterized by using the selective
agonist DAMGO to construct concentration-response curves
for each of the GABA inputs (Figure 3C). The concentration-
response curve for the RMTg input was adapted from a previous
study (Matsui and Williams, 2011). The maximum inhibition of
GABA-A IPSCs from the RMTg induced by DAMGO was
81.5% ± 10.2%, whereas the inhibition of the GABA-A IPSCs
evoked from the NAc and VTA interneurons was 52.8% ±
6.8% and 35.2% ± 8.7%, respectively. The EC50 was similar
for each of the GABA pathways (65 nM, 95% confidence interval
[CI] = 32–136 nM for RMTg; 163 nM,CI = 90–293 nM for NAc; and
79 nM CI = 21–297 nM for VTA). Thus, the potency of MOR-
dependent inhibition of each GABA input did not differ; however,
the maximum effect of DAMGO was very different. Thus, opioid
inhibition of GABA-A IPSCs measured on dopamine neurons is
largely due to terminals arising from the RMTg.
Limited Tolerance from Interneurons
The presynaptic inhibition of GABA release by opioids following
chronic morphine treatment has been reported to vary depend-
ing on the synapse, differences in the downstream signaling
pathways, and treatment protocols (Fyfe et al., 2010; Hack
et al., 2003; Ingram et al., 1998; Pennock and Hentges, 2011).
The inhibition of GABA release onto dopamine neurons after
chronic morphine treatment was examined from (1) interneurons
of the VTA, (2) the RMTg, and (3) the NAc by expressing ChR2
in each area. Approximately 1–2 weeks after virus injection,
osmotic mini pumps were implanted subcutaneously. Morphine
was released (50 mg,kg1,d1) for a week. Brain slices were
prepared in morphine-free ACSF and washed at least 2 hr to
remove the residual morphine. Full-field light stimulation
(1–1.5 ms duration paired stimuli; 50 ms interval every 30 s,
LED) or focal laser stimulation (3 ms duration paired stimuli;
50 ms interval every 30 s; 20–100 mm diameter) was applied to
evoke GABA-A IPSCs in dopamine neurons. The opioid-induced
inhibition of IPSCs evoked by each method was the same (p =
0.48), so the results were pooled.
Application of morphine (1 mM) caused small but significant
inhibition of GABA-A IPSCs evoked from VTA interneurons in
control animals (88.9% ± 1.6% of control, n = 14, six animals,
t13 = 6.83, p < 0.001) (Figures 4A and 4C) and MTAs (93.3% ±
2.2% of control, n = 11, five animals, t10 = 3.05, p = 0.01) (Figures
4B and 4C). The inhibition induced by morphine was not signifi-
cantly different between slices from untreated or MTAs (t19 =
1.64, p = 0.11). Since the inhibition by morphine was small, the
sensitivity of IPSCs to ME, a more efficacious agonist, was
examined. This subsaturating concentration of ME (1 mM)
decreased the IPSC amplitude to 82.3% ± 3.6% of baseline in
slices from untreated animals (n = 43, 20 animals, t42 = 4.95,
p < 0.001) (Figures 4A and 4C). When a saturating concentrationNeuron 82, 1346–1356, June 18, 2014 ª2014 Elsevier Inc. 1349
Figure 5. Chronic Morphine Treatment Reduced the Inhibition of
GABA IPSCs from RMTg
ChR2 was expressed in the RMTg, and GABA-A IPSCs were recorded from
dopamine neurons in the VTA/SN. Pairs of LED flashes (0.3 ms; 50 ms interval;
473 nm) were used to evoke IPSCs.
(A) Superimposed traces of paired GABA-A IPSCs from control animals.
Morphine inhibited GABA-A IPSCs, and subsequent application of antagonist
naloxone (1 mM) reversed that inhibition.
(B) Superimposed traces of GABA-A IPSCs fromMTAs. Morphine caused less
inhibition of IPSCs in MTA compared to control animals.
(C) Summary graph comparing the amount of inhibition induced by morphine
(1 mM) and ME (1 mM) in slices from control animals (black) and MTAs (gray).
(D) Time course of the naloxone-induced increase in GABA-A IPSCs from
RMTg comparing control versus MTA. Slices were prepared andmaintained in
morphine (1 mM), and naloxone-reversed IPSCs were plotted every minute.
The amplitude was normalized to the average over the first 10 min prior to
naloxone application. RMTg inputs from both control animals and MTAs
increased significantly. The increase in slices from untreated animals was
significantly larger than in slices from MTAs. Traces shown are the average of
five sweeps. Error bars indicate SEM. *p < 0.05 and **p < 0.001 by unpaired
two-tailed Student’s t test.
Figure 4. Opioid Inhibition of IPSCs Evoked from Interneurons in
Slices from MTAs
ChR2 was expressed in the VTA and GABA-A IPSCs were recorded from
dopamine neurons in the VTA/SN. LED flashes (0.2–0.4 ms; 50 ms interval;
473 nm) were used to evoke IPSCs.
(A) Superimposed traces of GABA-A IPSCs from control animals. Morphine
(1 mM) and ME (1 mM) application caused a small and significant inhibition of
GABA-A IPSCs.
(B) Superimposed traces of IPSCs fromMTAs. Morphine (1 mM) andME (1 mM)
again caused a very small inhibition of the IPSCs.
(C) Summary graph comparing the amount of inhibition in control (black) and
MTA (gray) by morphine (1 mM) and ME (1 mM). The inhibition induced by
morphine and ME was significant, but there was no difference between the
inhibition in slices from untreated animals versus MTAs. Traces shown are
averages of five sweeps. Error bars indicate SEM. Not significant (NS) un-
paired two-tailed Student’s t test.
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GABA Input to the Ventral Midbrainof ME (10 mM) was used, GABA-A IPSCs were inhibited to
58.5% ± 3.17% (n = 3) of control, similar to the inhibition medi-
ated by DAMGO (1 mM, 66.0% ± 5.3% of control). In slices
from MTAs, the subsaturating concentration of ME (1 mM)
decreased the IPSC to 84.2% ± 2.9% of control (n = 13, four
animals, t12 = 5.37, p < 0.001) (Figures 4B and 4C)—the same
as in slices from untreated animals. Thus, there was no signifi-
cant tolerance at synapses between interneurons and dopamine
neurons (t45 = 0.41, p = 0.69). Likewise, there was no change in
PPR (untreated: from 0.60 ± 0.03 to 0.65 ± 0.05, n = 43, t42 = 1.00,
p = 0.32; MATs: from 0.70 ± 0.04 to 0.73 ± 0.05, n = 13, t12 = 1.25,
p = 0.24). Thus, chronic morphine treatment did not alter the
opioid sensitivity of GABA-A IPSCs from interneurons.
Tolerance to Morphine-RMTg
The opioid inhibition of GABA-A IPSCs from the RMTg to dopa-
mine neurons was examined in slices from control and MTAs.
Using a small volume of viral injection, the expression of ChR2
was limited to the RMTg (Matsui andWilliams, 2011). Recordings
were made from dopamine neurons and wide-field light stimula-
tion (1–1.5 ms duration paired stimuli; 50 ms interval every 30 s
with LED) was used to evoke GABA IPSCs. In slices from un-
treated animals, morphine (1 mM) inhibited IPSCs to 53.9% ±
3.0% of control (n = 16, six animals, t15 = 15.6, p < 0.0001, Stu-1350 Neuron 82, 1346–1356, June 18, 2014 ª2014 Elsevier Inc.dent’s t test) (Figures 5A and 5C). Morphine also inhibited IPSCs
in slices from MTAs to 68.4% ± 4.4% of control (n = 10, five an-
imals, t9 = 7.20, p < 0.0001), and this inhibition was significantly
Figure 6. Naloxone Reversal of Morphine Inhibition in the VTA
and NAc
Slices were prepared and maintained in morphine (1 mM). Superfusion of
naloxone increased GABA-A IPSCs.
(A) Representative traces of IPSCs from VTA input taken from control (left) and
MTAs (right). Red traces show that naloxone caused a small increase in IPSCs
from the VTA input.
(B) Representative traces of IPSCs from NAc in control (left) and MTA (right).
(C) Summary graph shows the naloxone-induced increase in IPSCs from the
VTA and NAc in control animals and MTAs. In VTA and NAc, there was no
difference in the naloxone-induced increase in IPSCs between control animals
and MTAs. Traces shown are an average of five sweeps. Error bars indicate
SEM. NS indicated not significant, as determined by an unpaired two-tailed
Student’s t test.
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GABA Input to the Ventral Midbrainsmaller than in untreated animals (t16 = 2.74, p = 0.01) (Figures 5B
and 5C). In slices from control animals, the PPR significantly
increased from 0.68 ± 0.04 in baseline to 0.92 ± 0.07 in morphine
(n = 16, t15 = 5.01, p = 0.0001) (Figure 5D). In slices from
morphine treatment animals, the PPR also increased from
0.69 ± 0.08 to 0.90 ± 0.06 (n = 9, t8 = 5.57, p = 0.0005) (Figure 5D).
Thus, the inhibition of GABA-A IPSCs was consistent with a
presynaptic mechanism.
The sensitivity of the RMTg input to ME (1 mM) was also exam-
ined in slices from control and MTAs. ME (1 mM) decreased
GABA-A IPSCs in slices from both control and MTAs (untreated:
26.2% ± 3.8% of control, n = 31, 15 animals, t30 = 19.2, p <
0.0001; morphine treated: 47.6% ± 4.5% of control, n = 10,
four animals, t9 = 11.6, p < 0.0001), and the degree of inhibition
was significantly greater in slices from untreated animals (t23 =
3.61, p = 0.001) (Figure 5C). The PPR was also increased
(untreated: 0.79 ± 0.06 to 1.21 ± 0.14, n = 6, t5 = 5.32, p =
0.003; morphine treated: 0.75 ± 0.05 to 0.97 ± 0.06, n = 10,
t9 = 5.98, p = 0.0002) (Figure 5E). The results indicate that chronic
morphine treatment causes a decrease in the sensitivity to opi-
oids and is taken as a sign of tolerance.
To examine acute withdrawal, brain slices from both untreated
and MTAs were prepared and maintained in morphine (1 mM).
This concentration was chosen because it mimics the circulating
concentration in MTAs (Levitt andWilliams, 2012; Quillinan et al.,
2011). GABA-A IPSCs from the RMTg were evoked, and acute
withdrawal was induced with the addition of naloxone (1 mM).
In slices from untreated animals, naloxone reversed themorphine-induced inhibition reaching a steady state within
2min. The average amplitude of the IPSCswasmeasured before
and 4–10 min after application of naloxone. In slices from control
animals, the GABA IPSCs from the RMTg increased to 256.1% ±
37.3% of baseline (n = 11, five animals, t10 = 4.18, p = 0.002),
whereas the amplitude was only increased by 148.3 ± 14.6%
in slices fromMTAs (n = 13, 8 animals, t12 = 3.30, p = 0.006) (Fig-
ure 5D). The change in GABA-A IPSC amplitude was significantly
greater in slices from control animals (t13 = 2.69, p = 0.018) (Fig-
ure 5D) and is consistent with the development of tolerance,
without an indication of a withdrawal-induced increase in
GABA release. The PPR was also decreased in slices from
both untreated animals (from 1.17 ± 0.11 to 0.82 ± 0.08, n =
10, t9 = 4.69, p = 0.001) and MTAs (from 1.05 ± 0.10 to 0.68 ±
0.05, n = 12, t11 = 5.21, p = 0.0003). The time constant of decay
of the IPSCwas similar in slices from both groups (8.11 ± 0.44ms
and 8.08 ± 0.40 ms, respectively), suggesting that there was no
obvious change in postsynaptic GABA receptor expression.
Lack of Withdrawal—VTA and NAc
GABA IPSCs from interneurons in the VTA and projections from
the NAc were examined in slices from untreated and MTAs that
were maintained in morphine (1 mM). Acute withdrawal was
induced by addition of naloxone (1 mM). The amplitude of IPSCs
evoked from VTA interneuron terminals increased following
application of naloxone to a similar degree in slices from un-
treated animals and MTAs (untreated were 114.3% ± 10.6%
and MTAs were 113.8% ± 4.5% of control; t10 = 0.0088, p =
0.99, Student’s t test unpaired comparison) (Figures 6A
and 6C). IPSCs evoked from the NAc were also increased
following the application of naloxone (1 mM) in slices from un-
treated animals (130.2% ± 5.50% of baseline, n = 8, t7 = 5.50,
p = 0.0009) and MTAs (133.1% ± 7.81% of control, n = 7, t6 =
4.23, p = 0.0055) (Figures 6B and 6C). The increase in IPSC
amplitude was not significantly different between untreated
animals and MTAs (t11 = 0.30, p = 0.77, Student’s t test unpaired
comparison). Taken together, the results indicate that these
GABA inputs to dopamine neurons did not exhibit a significant
rebound increase in GABA release following acute withdrawal
from morphine.
The Role of Adenosine Receptors
Previous studies have found that adenosine tone was elevated
during withdrawal from chronic morphine treatment, resulting
in an inhibition of GABA release through activation of presynaptic
adenosine receptors in the VTA/SN (Bonci and Williams, 1996;
Shoji et al., 1999). It is not known which GABAergic terminals
express A1 adenosine receptors. The IPSCs evoked from the
RMTg were insensitive to the adenosine receptor agonist N6-
cyclopentyladenosie (CPA 1 mM; 98.7% ± 1.9%, n = 21, four an-
imals, t20 = 0.69, p = 0.50) (Figures 7A and 7B). IPSCs evoked
from local interneurons were decreased to 70.7%± 2.8%of con-
trol (n = 19, three animals, t18 = 10.6, p < 0.0001) by CPA (1 mM)
without a change in PPR (n = 14, t13 = 1.21, p = 0.25). In contrast,
the IPSCs evoked from the NAc input were inhibited by CPA to
21.6% ± 5.3% of control (n = 11, nine animals, t10 = 14.8, p <
0.0001) (Figures 7A and 7B), and the PPR was significantly
increased from 0.88 to 1.36 (n = 8, t7 = 2.57, p = 0.037).Neuron 82, 1346–1356, June 18, 2014 ª2014 Elsevier Inc. 1351
Figure 7. Adenosine Receptor Regulation of GABA-A IPSCs in
Dopamine Neurons
(A) Representative traces of IPSCs evoked from theRMTg, NAc, and VTA in the
control (black) and in the presence of the adenosine agonist CPA (1 mM; red)
and subsequent application of the adenosine antagonist DPCPX (200 nM;
gray).
(B) Summary graph of the inhibition of IPSCs induced by CPA (1 mM).
(C) Summary graph of the increase in the GABA IPSCs induced by the aden-
osine receptor antagonist DPCPX (200 nM) in slices from untreated animals
and MTAs. Traces shown are an average of five sweeps. Error bars indicate
SEM. *p < 0.05 and **p < 0.001 by one-way ANOVA with Bonferroni’s post hoc
test or unpaired two-tailed Student’s t test.
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GABA Input to the Ventral MidbrainBasal adenosine tone was examined using application of
the adenosine A1 receptor antagonist DPCPX (200 nM). DPCPX
failed to increase GABA-A IPSCs evoked from the RMTg in slices
from untreated animals and MTAs (untreated: 101.7% ± 2.6% of
control n = 19, six animals; MTAs: 101.9% ± 1.5%, n = 14, six
animals; t27 = 0.06, p = 0.95, Student’s t test unpaired compari-
son) (Figure 7C). The IPSCs evoked from VTA interneurons were
significantly increased in amplitude by DPCPX (200 nM) in slices
from control animals and MTAs (untreated: 108.4% ± 3.1%, n =
11, five animals; MTAs: 110.2% ± 4.2%, n = 9, six animals).
Thus, there was some adenosine tone in slices from untreated
animals; however, there was no significant difference in
increasing GABA-A IPSCs after chronic morphine treatment
(t20 = 0.34, p = 0.74).
IPSCs evoked from the NAc in slices from untreated animals
were also increased by DPCPX (107.6% ± 3.4%, n = 11, seven
animals, t10 = 2.26, p = 0.047, Student’s t test), suggesting inhi-
bition of basal adenosine receptor activation. In slices from
MTAs, however, DPCPX increased the IPSCs to 131.9% ±
7.0% of control (n = 11, four animals, t10 = 4.57, p = 0.001,
Student’s t test), significantly larger than in slices from untreated
animals (t14 = 3.14, p = 0.0071, Student’s t test unpaired compar-1352 Neuron 82, 1346–1356, June 18, 2014 ª2014 Elsevier Inc.ison). Thus, adenosine tone was elevated in slices during acute
withdrawal, and this increase in adenosine receptor activation
opposed the naloxone-induced increase in GABA release.
DISCUSSION
Opioids inhibit GABA IPSCs on dopamine neurons, and the
amplitude of that inhibition is dependent on the afferent pathway.
The inhibition of IPSCs produced by opioid agonists was the
greatest on afferents from the RMTg, the least on local inter-
neurons and intermediate on the projections from the NAc. The
sensitivity to adenosine, on the other hand, was the greatest
for inputs from the NAc and the least at terminals arising from
the RMTg. The increase in adenosine tone in slices from MTAs
suggests that these GABA releasing terminals play very different
roles in the acute and chronic actions of opioids.
MOR Agonist Regulation of VTA GABA Neurons
It is established that opioids hyperpolarize GABA neurons in the
VTA by activating a GIRK conductance (Chieng et al., 2011;
Jalabert et al., 2011; Johnson and North, 1992). Likewise,
opioids activate a potassium conductance in neurons of the
RMTg (Matsui and Williams, 2011). There is, however, a marked
difference in the amount of presynaptic inhibition induced by
opioids. GABA input from the RMTg may effectively suppress
the activity of dopamine neurons. This is supported by experi-
ments carried out in vivo where infusion of morphine into the
RMTg increased the firing rate of dopamine neurons (Jalabert
et al., 2011). When morphine was infused into the VTA, there
was no change in the firing of dopamine neurons (Jalabert
et al., 2011). The increased inhibition observed from the RMTg
may result from (1) a higher expression of MORs, (2) a difference
in the coupling efficiency, or (3) GABA neurons in the VTAmay be
a heterogeneous population of opioid-sensitive and -insensitive
neurons.
The regulation of dopamine cells through the activity of
interneurons in the VTA has also been established. When
GABA neurons in the VTA were selectively stimulated using
ChR2 in mice, aversive behavior and a reduction of free-reward
consumption was observed (Tan et al., 2012; van Zessen et al.,
2012). These behavioral consequences were thought to result
from the GABA-dependent inhibition of dopamine neurons.
The present study in the rat supports these observations, since
activation of GABA neurons in the VTA reliably evoked IPSCs
in dopamine neurons. Thus, although GABA neurons in the
VTA contribute to the activity of dopamine cells (Li et al., 2012;
Steffensen et al., 1998), it appears that opioids have a minimal
role in this pathway.
There are other GABA inputs to the ventral midbrain, including
the ventral pallidum/globus pallidus, laterodorsal tegmentum,
pedunculopontine nuclei and diagonal band of Broca, and bed
nucleus of the stria terminalis (Bolam and Smith, 1990; Charara
et al., 1996; Hjelmstad et al., 2013; Omelchenko and Sesack,
2005; Smith and Bolam, 1990; Tepper et al., 1995; Tepper and
Lee, 2007; Watabe-Uchida et al., 2012). Using a saturating
concentration of DAMGO (1 mM), the ChR2-induced GABA
release from terminals originating in the ventral pallidum was
decreased by about 30% on both dopamine and GABA neurons
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GABA Input to the Ventral Midbrainin the VTA (Hjelmstad et al., 2013). The role of these GABA
afferent pathways during opioid withdrawal remains to be
determined.
A Direct Projection from the NAc to Dopamine Neurons
A direct connection from neurons in the NAc to dopamine
neurons was identified in the present study. This observation
is unlike previous work that did not observe a direct NAc-dopa-
mine neuron connection (Chuhma et al., 2011; Xia et al., 2011)
or that found only a subset of non-GABA neurons that received
a direct GABA input (Bocklisch et al., 2013). In the present
study, GABA input onto dopamine neurons from NAc was
also observed infrequently compared to the frequency of
GABA inputs onto GABA neurons in the VTA and SNr. A recent
trans-synaptic tracing study found that striatal subregions con-
sisting of patch and matrix send differential projections to dopa-
mine and GABA neurons, respectively (Watabe-Uchida et al.,
2012). In MOR knockout mice, prodynorphin-positive MSNs in
striatal patches and the NAc project to the VTA/SN and the acti-
vation of re-expressed MORs in this pathway disinhibit dopa-
mine neurons (Cui et al., 2014). The GABA-A IPSCs from the
NAc to dopamine neurons in the present study were inhibited
by dopamine acting on D2 receptors. This result was unex-
pected based on the assumption that solely direct pathway
MSNs known to express D1 receptors project from the NAc to
dopamine neurons. However, previous evidence suggests that
a small percentage of MSNs coexpressed D1 and D2 receptors
(Lester et al., 1993; Perreault et al., 2010; Thibault et al., 2013).
Whether the opioid-sensitive input from NAc to dopamine
neurons described in this study originates from the so-called
‘‘indirect pathway’’ or an unidentified subset of neurons is not
known.
Tolerance and Withdrawal after Chronic Morphine
Treatment
Adaptive changes in transmitter release at various terminals
following chronic morphine treatment vary widely, ranging
from tolerance (Bonci and Williams, 1997; Fyfe et al., 2010;
North and Vitek, 1980) to sensitization (Ingram et al., 1998;
Pennock et al., 2012) and the addition of new opioid-sensitive,
cAMP-dependent effectors (Bagley et al., 2005; Hack et al.,
2003). These inconsistencies could be due to differences in (1)
MOR/effector coupling, (2) the efficiency of coupling, (3) location
of synapses, (4) species, and (5) the protocol used for chronic
morphine treatment. For example, there are distinct difference
in the opioid-sensitive GABA synapses in the PAG between
rats and mice using the same chronic morphine treatment
(Hack et al., 2003; Ingram et al., 1998). A withdrawal-induced
increase in GABA release was revealed in the rat PAG. In the
mouse PAG, however, the increase in GABA release was only
observed after inhibition of presynaptic adenosine receptors.
There are also marked differences in results obtained using
different morphine treatment protocols. The results obtained
using continuous or repeated injection of morphine vary consid-
erably. Continuous exposure tomorphine resulted in the addition
of an opioid-sensitive, cAMP/PKA-dependent effector pathway
that resulted in an additional inhibition of GABA IPSCs (Ingram
et al., 1998). However, repeated injections of morphine (i.e.,twice a daily) failed to induced the cAMP/PKA mechanism
(Fyfe et al., 2010).
This study supports previous observations made in the guinea
pig VTA that chronic morphine treatment results in signs of
withdrawal (Bonci and Williams, 1997). Although tolerance
developed at RMTg terminals, an adenosine-dependent sign of
withdrawal was not observed due to lack of A1 adenosine recep-
tors. Expression of tolerance or withdrawal was not observed at
terminals from VTA interneurons. In contrast, there was a signif-
icant adenosine-dependent inhibition of GABA release from NAc
terminals and an increase in the adenosine tone in slices from
MTAs. The present results are similar to experiments that exam-
ined the GABA-B IPSP in dopamine neurons in guinea pig slices
(Shoji et al., 1999). That study proposed that projections from the
striatum and NAc selectively activated GABA-B receptors on
dopamine neurons based on pharmacological experiments
(Shoji et al., 1999). Similar experiments using optogenetic stim-
ulation have not been reported.
There were marked differences in the sensitivity of GABA-A
IPSCs to the adenosine agonist, CPA, with selective activation
of specific GABA-A IPSCs using ChR2 expression. With the
use of electrical stimulation, most IPSCs were insensitive to
the activation of adenosine receptors. There were, however, a
few experiments where the IPSC was almost completely
blocked by CPA. Thus, it appears that electrical stimulation often
results in the activation of adenosine-insensitive terminals that
most likely arise from local interneurons or projections from the
RMTg.
CONCLUSION
The present results indicate that opioid receptor-dependent
disinhibition of dopamine neurons can be mediated by multiple
GABA inputs. Given the distinct difference in the amount of
opioid inhibition between the GABA afferents, it seems likely
that the projection from the RMTg plays a dominant role in acute
opioid disinhibition of dopamine neurons. This is particularly
clear when using the partial agonist morphine, which inhibited
GABA IPSCs from interneurons and NAc afferents to a much
lesser extent compared with those from the RMTg. After chronic
morphine treatment, tolerance to opioids and a withdrawal-
induced increase in GABA IPSCs were expressed in separate
terminals. Thus, the balance of inhibitory input to dopamine neu-
rons was modulated by chronic morphine treatment.
EXPERIMENTAL PROCEDURES
All procedures were performed in accordance with the guidelines of Oregon
Health & Science University and the Animal Care and Use Committees
approved all of the experimental procedures.
Intracerebral Microinjections
Male and female Sprague-Dawley rats (p20-22, Charles River Laboratories)
were used for intracerebral microinjections. Rats were anesthetized with
isoflurane and immobilized in a Stereotaxic Alignment System (Kopf Instru-
ments). ChR2 was expressed using adeno-associated virus (AAV) constructs
prepared by the Vollum Institute Viral Core (Portland). The vector AAV-CAG-
ChR2-Venus (serotype DJ, 100 nl; 53 1012 genomes/ml) was injected bilater-
ally using a nanoject II (Drummond Scientific Company) into VTA (from bregma
[in mm]: 4.35 anteroposterior, ±0.8 lateral, 7.5 ventral), NAc (from bregmaNeuron 82, 1346–1356, June 18, 2014 ª2014 Elsevier Inc. 1353
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GABA Input to the Ventral Midbrain[in mm]: 1.0 anteroposterior, ±1.8 lateral,5.6 ventral), or RMTg (from bregma
[in mm]: 5.7 anteroposterior, ±0.8 lateral, 7.25 ventral]. Experiments were
performed in 55 of 61 rats where injections were successfully placed in the
VTA, 36 of 49 rats with injections in the NAc, and 35 of 41 rats with injections
in the RMTg. Acute brain slices were prepared 13–40 days after the VTA injec-
tion, 21–28 days after NAc injection, and 17–35 days after RMTg injections.
ChR2 expression at the injection sites was confirmed before experiments.
Animals were excluded from the study when ChR2 expression spread outside
of the target.
Chronic Morphine Treatment
Rats were chronically treated with morphine sulfate (National Institute on Drug
Abuse) using continuous-release osmotic pumps (2ML1; Alzet, Cupertino).
The osmotic pumps have a mean filled volume of 2 ml and released 10.1 ±
0.2 ml/hr. Rats were anesthetized with isoflurane a few weeks after ChR2 injec-
tions. A small incision was made to insert an osmotic pump subcutaneously.
Each osmotic pump delivered 50 mg,kg1,d1 of morphine in water. Experi-
ments were performed 6–8 days after implantation.
Slice Preparation and Recording
Rats (150–300 g) were anesthetized with isoflurane and killed. Brains were
quickly removed and placed in a vibratome (Leica). Sagittal slices (220–
230 mm) were prepared in ice-cold physiological solution containing the
following (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 1.4 NaH2PO4, 25
NaHCO3, 11 D-glucose, and 0.005 MK-801. Slices were incubated in warm
(35C) 95%O2/5%CO2 oxygenated saline containing MK-801 (10 mM) for at
least 30 min. Slices containing the midbrain or NAc were then transferred to
the recording chamber that was constantly perfused with 35C 95%O2/5%
CO2 oxygenated saline solution at the rate of 1.5–2 ml/min.
Midbrain and NAc neurons were visualized with a 403 water-immersion
objective on an upright fluorescent microscope (BX51WI, Olympus USA)
equipped with gradient contrast infrared optics. Wide-field activation of
ChR2 was achieved with collimated light from an LED (470 nm; Thorlabs). A
20–100 mm diameter focal laser spot (473 nm laser, IkeCool) was used to
activate a ChR2 within the VTA using a 403 objective. Physiological identifica-
tion of dopamine neurons was based on the presence of D2-autoreceptor-
mediated GIRK currents and the rate of spontaneous action potential activity
(1–5 Hz) with spike widths R1.2 ms (Chieng et al., 2011; Ford et al., 2006; Li
et al., 2012; Ungless et al., 2004). The identification of MSNs and CINs were
based on the size/membrane capacitance, the resting membrane potential,
and opioid sensitivity (Britt and McGehee, 2008).
Whole-cell voltage clamp recordings were made using an Axopatch-1D
amplifier (Molecular Devices). All recordings were digitized at 10 kHz and
filtered at 5 kHz. GABA-A IPSCs were recorded with patch pipettes
(2–2.5 MU) filled with an internal solution containing the following (in mM):
57.5 KCl, 57.5 K-methylsulfate, 20 NaCl, 1.5 MgCl2, 5 HEPES (K), 10 BAPTA,
2 ATP, 0.2 GTP, and 10 phosphocreatine [pH 7.35], 280 mOsm. All neurons
were voltage clamped at60mV. Series resistancewasmonitored throughout
the experiment (range; 3–15 MU) and compensated by 80%. GABA-A IPSCs
were evoked by the activation of ChR2 (two stimuli at 20 Hz; every 20 or
30 s). All recordings were performed in the presence of 6,7-dinitroquinoxa-
line-2,3 (1H,4H)-dione (DNQX; 10 mM) to isolate GABA-A IPSCs. Naloxone
was applied following DAMGO and U69593 in order to reverse the inhibition
in a reasonable period of time.
Data Analysis
Data were collected on a Macintosh computer using AxoGraphX (Axograph
Scientific) and stored for offline analysis. Statistical significance was assessed
with Student’s t tests or ANOVA (Bonferonni’s post hoc analysis); *p < 0.05 and
**p < 0.001. Data are presented as mean ±SEM.
In Situ Hybridization
Seventeen days after virus containing the ChR2-Venus construct was injected,
rats were anesthetized with an overdose of pentobarbital (400 mg/kg via intra-
peritoneal injection) and transcardially perfused with 10% sucrose followed by
4% formaldehyde in PBS. Brains were removed and postfixed overnight in 4%
formaldehyde at 4C. The in situ hybridizations were performed as previously1354 Neuron 82, 1346–1356, June 18, 2014 ª2014 Elsevier Inc.described (Jarvie and Hentges, 2012) with the exception that glutamate decar-
boxylase (Gad) 65 and 67 mRNAs were simultaneously detected to reveal all
Gad-positive cells with one fluorophore. In brief, sagittal slices (50 mm) contain-
ing the VTA were prepared on a vibratome and placed in diethylpyrocarbon-
ate-treated PBS. The tissue was exposed to proteinase K (10 mg/mL) diluted
in PBS containing 0.1% Tween-20 (PBST) for 15min at room temperature. Tis-
suewas then rinsed in PBST containing glycine (2mg/mL) to inactivate the pro-
teinase K and then subjected to two 5 min washes in PBST. Slices were then
postfixed with 4% paraformaldehyde/0.2% gluteraldehyde in PBST for 20 min
at room temperature and then rinsed in PBST. Sections were dehydrated in
ethanol of increasing concentrations (50%, 70%, 95%, and 100%) and then
rinsed briefly with PBST before being placed into hybridization buffer contain-
ing the following: 66% formamide, 13% dextran, 260 mM NaCl, 13 mM Tris,
1.3 mM EDTA, 0.5 mg/mL yeast tRNA, 10 mM DTT, and 13 Denhardt’s Solu-
tion (pH 8.0). After 1 hr in hybridization, buffer probes were added.
Digoxigenin (DIG)-labeled antisense RNA probes for the 65 and 67 kDa
isoforms of GAD were made as previously described (Jarvie and Hentges,
2012). The Gad67 probe corresponded to base pairs 1,196–2,001 of GenBank
accession number NM_017007.1, which has 94% homology with the cDNA for
rat Gad67. Gad65 was labeled using two probes simultaneously correspond-
ing to base pairs 312–945 and 940–1,770 of GenBank accession number
NM_012563.1, both of which have 100% homology with rat cDNA. Each probe
was used at a concentration of 150 pg/ml. The Gad67 probe was hybridized
first for 18–20 hr at 70C, then the tissue was moved into hybridization buffer
containing the Gad65 probes and incubated for 20 hr at 52C. Sense probes
were used to establish specificity of antisense probes.
Following hybridization, sections were subjected to three 30 min washes
with 50% formamide in 5XSSC (pH 4.5) and three 30 min washes with 50%
formamide in 23 SSC at 60C. Tissue was then digested for 30 min at 37C
with RNase A (20 mg/mL) in Tris buffer plus 0.5 M NaCl (pH 8.0), then washed
three times in TNT (0.1MTris-HCl [pH 7.5], 0.15MNaCl, 0.05%Tween-20), and
blocked for 1 hr at room temperature in TNB (TN plus 0.5% Blocking Reagent
provided in the TSA kit, Perkin Elmer). Venus fluorescence was quenched by
the in situ hybridization procedure; however, antigenicity remained, allowing
immunohistochemical detection of the ChR2-Venus. For detection of Venus
and DIG, sections were incubated overnight at 4Cwith sheep anti-DIG conju-
gated to horseradish peroxidase (Roche Applied Sciences, 1:1,000) and
chicken anti-GFP (abcam ab13970, 1:2,000) in TNB. After three washes in
TNT, sections were subjected to a 30 min biotin amplification using a TSA
Plus Biotin Kit (Perkin Elmer) following manufacturer’s instructions. After biotin
amplification, sections were incubated for 30 min in streptavidin conjugated to
Alexa Fluor 488 (Invitrogen, 1:1,000) and then washed three times in TNT.
Finally, sections were incubated for 2 hr in donkey anti-chicken conjugated
to Alexa Fluor 647 secondary antibody (Jackson ImmunoResearch) and
washed 3 times in TNT. Sections were then placed on glass slides and cover-
slipped using Aqua Poly/Mount (Polysciences, Inc., Warrington).
Immunofluorescence
The retrograde tracer Cholera Toxin B (CTX) conjugated to Alexa Fluor 488
(Invitrogen, 1:1,000) was injected into the rat VTA (coordinates x = ±0.8, y =
4.35, z = 7.5 from Bregma) at 21 days postnatal. Fourteen days following
the injection, rats were anesthetized with isoflurane and transcardially
perfused with 10% sucrose followed by 4% formaldehyde in PBS. Brains
were removed and postfixed overnight in 4% formaldehyde at 4C. Coronal
slices (50 mm) containing the NAc were prepared using a vibratome and rinsed
33 in PBS. Slices were rinsed in blocking/permeabilizing solution (0.5% fish
skin gelatin, 0.2% Triton-X) for 2 hr then incubated in Methionine Enkephalin
Antibody (Immunostar #20065) at a 1:100 dilution in blocking solution for
2 hr at room temperature followed by overnight incubation at 4C. Slices
were rinsed 33 in PBS (15, 45, and 60 min) and then incubated for 1 hr in an
Alexa Fluor 647 secondary antibody (Invitrogen goat anti-rabbit, 1:1,000).
Slices were rinsed 43 in PBS (5, 10, 15, and 30 min) and mounted on glass
slides in preparation for confocal microscopy.
Image and Analysis
Images were collected with a Zeiss laser scanning confocal LSM780 micro-
scope. For in situ hybridization, z stack tile images were taken from all of the
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GABA Input to the Ventral Midbraintissue containing VTA and SNc. The percentage of colocalized neurons was
calculated by counting the total number of colabeled neurons divided by the
total ChR2-positive neurons. In order to count the neurons colabeling ChR-2
and GAD, ChR2-positive neurons were identified first and observed the coloc-
alization with GAD65/67. For immunofluorescent images, z stack tile images
were taken using a 203 lens with a 23 digital zoom. The 488 and 647 fluoro-
phores have nonoverlapping spectra; however, wemanually set amaximum of
600 nm for the 488 fluorophore and a minimum of 640 nm for the 647 fluoro-
phore during imaging to ensure against bleed-through. Ten slices spanning
the NAc from each of three animals were visualized. To determine colocali-
zation, CTX-positive neurons were identified first and then the colocalization
with Enkephalin was determined. Colocalization was confirmed by at least
three unbiased individuals. The images were analyzed using Fiji software
(National Institute of Health, Bethesda).
Materials
Drugs were applied by bath perfusion. The solution containing [Met5]enkeph-
alin (ME) included the peptidase inhibitors bestatin hydrochloride (10 mM) and
thiorphan (1 mM). ME, [D-Ala2, N-Me-Phe4, Gly5-ol]enkephalin (DAMGO),
(+)-(5a,7a,8b)-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benze-
neacetamide (U69593), naloxone, picrotoxin, SR 95531, dopamine, sulpiride,
4-aminopyridine, DNQX, and TTX were obtained from Sigma-Aldrich
(St. Louis). MK-801 was purchased from Ascent Scientific (Weston-Super-
Mare). CGP55845, N-Cyclopentyladenosine (CPA), 8-Cyclopentyl-1,3-dipro-
pylxanthine (DPCPX), and quinpirole were obtained from Tocris Bioscience
(Ellisville).
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